ストックスクリーナーアプリを入手
53.62
0.78%
-0.4744
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Navigating a Potential 62.41% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
BMRN stock down on mixed results from rare disease therapy study - MSN
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Understanding the Setup: (BMRN) and Scalable Risk - Stock Traders Daily
BMRN Maintains Rating by Canaccord Genuity -- Price Target Lowered to $111 - GuruFocus
Citigroup and I Are Aligned on These 3 Mid-Cap Biopharma Stocks - TheStreet Pro
H.C. Wainwright reiterates Neutral on BioMarin stock, $50 target By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral on BioMarin stock, $50 target - Investing.com
Layoff Tracker: AbbVie, Novartis slash US headcount - BioSpace
BioMarin (BMRN) EVP Cristin Hubbard reports 2,318-share tax-withholding disposition - Stock Titan
BioMarin Reveals Dwarfism Study Data, Stock Soars - Benzinga
BioMarin Looks To Expand Voxzogo Franchise With Positive Hypochondroplasia Data - Citeline News & Insights
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid - Fierce Pharma
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint - Insider Monkey
BioMarin’s Voxzogo hits Phase III goal in hypochondroplasia - The Pharma Letter
BioMarin Pharmaceutical stock (US09061G1013): Voxzogo Phase 3 success sparks growth hopes - AD HOC NEWS
BioMarin moves to expand Voxzogo into hypochondroplasia with pivotal win - FirstWord Pharma
BioMarin Pharmaceutical (BMRN) 10K Form and Latest SEC Filings 2026 - MarketBeat
BioMarin’s Voxzogo meets primary endpoint in hypochondroplasia trial - Investing.com UK
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin’s Voxzogo meets primary endpoint in hypochondroplasia trial By Investing.com - Investing.com South Africa
BioMarin stock surges on positive hypochondroplasia trial data - Investing.com
BioMarin's drug shows significant growth gains in children in late-stage trial - marketscreener.com
BioMarin stock surges on positive hypochondroplasia trial data By Investing.com - Investing.com Nigeria
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia - PR Newswire
5 Best Low Priced Stocks to Buy for the Next 3 Years - Insider Monkey
BioMarin Trial Setback Puts Rare Disease Pipeline And Valuation In Focus - Sahm
BMRN Maintained by B of A Securities -- Price Target Lowered to $80 - GuruFocus
BMRN Initiates Coverage by Citigroup -- Price Target Announced a - GuruFocus
BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug - MedCity News
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - The Globe and Mail
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
BioMarin’s SWOT analysis: rare disease biotech stock faces competitive headwinds - Investing.com
BioMarin drug acquired in buyout misses goal in rare disease study - BioPharma Dive
H.C. Wainwright cuts BioMarin stock price target after trial miss - Investing.com India
BioMarin rare disease biologic meets only 1 of 2 endpoints in phase 3 trial - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth - ChartMill
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop - BioSpace
H.C. Wainwright cuts BioMarin stock price target after trial miss By Investing.com - Investing.com Canada
Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50 - TradingView
Citigroup initiates coverage of BioMarin Pharmaceutical (BMRN) with buy recommendation - MSN
BioMarin (BMRN) Faces Setback in ENPP1 Deficiency Drug Trial - GuruFocus
BMRN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):